NewcelX prices $1.55 million private placement at premium to market

NewcelX Ltd. (Nasdaq: NCEL) announced on November 9, 2026 that it had entered into securities purchase agreements for a private placement priced at $3.29 per share. That price represents a 20% premium to the company's last closing price on November 6, 2026.¹

Under the deal, NewcelX is selling 471,125 common shares along with warrants to purchase 353,344 additional shares, with the warrants carrying a $3.75 exercise price, which works out to 137% of that same November 6 closing price.¹ Existing shareholders are participating in the round, and the deal is slated to close around November 23, 2026, pending customary closing conditions.¹

The company said the financing was led by international healthcare investors along with The Crushing T1 Foundation.

NewcelX said it plans to combine the new proceeds with its existing cash and a previously disclosed $25 million equity line to fund further work on NCEL-101, its lead type 1 diabetes program being developed with Eledon Pharmaceuticals.¹ Specifically, the company said the funds will support starting an FDA-mandated IND-enabling toxicology study, building out cell manufacturing capacity, and preparing for a Phase 1/2a trial targeted for 2027, in addition to general working capital needs.

CEO and Executive Chairman Ronen Twito said in the release that the financing arrives as the company moves toward IND-enabling studies after what he described as a successful Pre-IND meeting with the FDA, ahead of the planned 2027 Phase 1/2a trial with Eledon Pharmaceuticals.¹

The securities were sold in a private placement under Section 4(a)(2) of the Securities Act and Regulation D, and have not been registered under the Securities Act or applicable state securities laws, meaning they cannot be offered or sold in the U.S. absent an effective registration statement or applicable exemption.¹